ConserV Bioscience is a late-stage vaccine development company focused on advancing safe and effective vaccines that protect against endemic and emergent infectious diseases. ConserV Bioscience Limited, based in Oxfordshire, United Kingdom, is a clinical-stage vaccine development company focused on advancing safe and effective vaccines that protect against endemic and emergent infectious diseases. Founded in 2020 as a spin-out from PepTcell Limited, it has an experienced team of immunologists and molecular biologists. ConserV Bioscience is harnessing its novel in silico proprietary platform to identify highly conserved regions of viral proteins that contain a high number of reactive T-cell epitopes with extensive HLA coverage. These regions can then be delivered as vaccines using different platforms, such as synthetic peptides, mRNA, or DNA. ConserV Bioscience has a pipeline of eight vaccines at various stages of pre-clinical and clinical development including vaccine candidates to protect against broad-spectrum influenza (Phase III), mosquito-borne diseases (Phase II), HIV, Hepatitis C, Hepatitis B, Rotavirus, Chagas and broad-spectrum coronavirus.